Merck Infectious Disease Head Touts Diversity Of Post-Schering Merger Anti-Infective Portfolio
Executive Summary
BOSTON – Merck & Co.'s purchase of Schering-Plough created probably the most broad and comprehensive pipeline of anti-infective agents in the industry, according to Roger Pomerantz, Merck's senior vice president and global franchise head, infectious diseases.
You may also be interested in...
Novel Antibiotics At ICAAC Spur Optimism On Resistance Front
While short-term prospects are dim for new antibiotics to treat multi-drug-resistant pathogens – Gram-negative bacteria in particular – research presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy indicates a handful of novel compounds could be ready for prime time in as few as four or five years.
Novel Antibiotics At ICAAC Spur Optimism On Resistance Front
While short-term prospects are dim for new antibiotics to treat multi-drug-resistant pathogens – Gram-negative bacteria in particular – research presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy indicates a handful of novel compounds could be ready for prime time in as few as four or five years.
Merck's Backbone Is Cardiovascular, Infectious Disease After Pipeline Integration
Merck's late-stage pipeline includes more than 40 compounds in Phase II and Phase III development after combining with Schering-Plough's assets.